Literature DB >> 46854

Lymphoid cells in infectious mononucleosis classified according to T and B cell markers.

F Aiuti, G Rocchi, R D'Amelio, S Giunta, M Fiorilli.   

Abstract

It has been demonstrated that peripheral blood lymphocytes, particularly the "atypical" ones, are predominantly of the T type in infectious mononucleosis (IM). This is based on membrane marker studies (E rosettes, receptor for complement, receptor for Fc fragment of immunoglobulins (Ig), and membrane Ig) and by anti-T lymphocyte serum. On the other hand, lymphoblastoid cell lines derived from IM patients show the characteristics of B lymphocytes. This permits the suppostion that EBV infects B lymphocytes and stimulates them to proliferate. The cell proliferation is unlimited in vitro and is probably controlled in vivo by T cells. The reduction of cellular immunity in vivo, which contrasts with the high number of T cells in peripheral blood, could be explained by the fact that T cells are engaged in the regulation of B cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 46854     DOI: 10.1159/000231320

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

1.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

2.  Blastogenic response of purified human T-lymphocyte populations to Epstein-Barr virus (EBV).

Authors:  P Gergely; I Ernberg; G Klein; M Steinitz
Journal:  Clin Exp Immunol       Date:  1977-12       Impact factor: 4.330

Review 3.  Genetics of neoplasia--impact of ecogenetics on oncogenesis. A review.

Authors:  D T Purtilo; L Paquin; T Gindhart
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

4.  Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease.

Authors:  T A Shiftan; A P Caviles; J Mendelsohn
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.